Effects of Acute and Chronic Attenuation of Postprandial Hyperglycemia on Postglucose-load Endothelial Function in Insulin Resistant Individuals: Is Stimulation of First Phase Insulin Secretion Beneficial for the Endothelial Function?

Abstract

The aim of the study is to determine if attenuation of postprandial hyperglycemia, by acutely and chronically enhancing postprandial insulin secretion in insulin-resistant individuals, improves the endothelial dysfunction. We assessed postoral glucose-load endothelial function in 56 insulin-resistant subjects with the Flow-Mediated-Dilation (FMD) technique. We randomized subjects to intervention/control group, and examined the acute and chronic effect of nateglinide, an oral antidiabetic drug of rapid action. In the intervention group, postoral glucose-load (post-OGL) FMD delta values deteriorated when compared to pre-OGL values, most significantly at 3 h post-OGL, on the following days: on the first study day termed “Baseline day” (p=0.04); on both days after 3 months of nateglinide treatment [with nateglinide administered on study-day “acute+chronic” (p=0.01); and without nateglinide on study-day “Closing day”, p=0.001]. Post-OGL changes in the control group were nonsignificant both at Baseline and on Closing day. After a single dose of nateglinide “Acute day”, post-OGL FMD deterioration was abolished. There was an increment in post-OGL FMD delta values most significant at 2 h post-OGL (p=0.02). Insulin concentrations increased while glucose concentrations decreased on study-days with nateglinide when compared to study-days without (p=<0.001 for both insulin and glucose). Comparisons for insulin and glucose concentrations between days with nateglinide, and likewise between days without, showed no significant difference. Postglucose load endothelial dysfunction can be prevented by administration of nateglinide, however, after 3 months of nateglinide treatment, this effect is abolished. Chronically increased insulin secretion could counteract the initial beneficial effect of reduced glucose excursions. We found no relationship between postprandial hyperglycemia and post-OGL FMD.

Key words

insulin resistance - postprandial hyperglycemia - postprandial hyperinsulinemia - flow mediated dilation - impaired glucose tolerance - diabetes - 2hPG - atherosclerosis - cardiovascular disease

References

• 1 Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes.  Diabetologia. 2001;  44 ((Suppl 2)) S14-S21
• 2 DECODE Study Group; on behalf of the European Diabetes Epidemiology Group . Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-h diagnostic criteria.  Arch Intern Med. 2001;  161 397-405
• 3 Rodriguez BL, Abbott RD, Fujimoto W, Waitzfelder B, Chen R, Masaki K. et al . The American Diabetes Association and World Health Organization classifications for diabetes: their impact on diabetes prevalence and total and cardiovascular disease mortality in elderly Japanese-American men.  Diabetes Care. 2002;  25 951-955
• 4 Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study.  Diabetes Care. 1999;  22 920-924
• 5 Shaw JE, Hodge AM, Courten M de, Chitson P, Zimmet PZ. Isolated post-challenge hyperglycaemia confirmed as a risk factor for mortality.  Diabetologia. 1999;  42 1050-1054
• 6 Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years.  Diabetes Care. 1999;  22 233-240
• 7 Hanefeld M, Koehler C, Schaper F, Fuecker K, Henkel E, Temelkova-Kurktschiev T. Postprandial plasma glucose is an independent risk factor for increased carotid intima-media thickness in non-diabetic individuals.  Atherosclerosis. 1999;  144 229-235
• 8 DECODE Study Group . Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases?.  Diabetes Care. 2003;  26 688-696
• 9 Schachinger V, Zeiher AM. Atherosclerosis-associated endothelial dysfunction.  Z Kardiol. 2000;  89 ((Suppl 9)) IX/70-74
• 10 Ceriello A, Taboga C, Tonutti L, Quagliaro L, Piconi L, Bais B. et al . Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment.  Circulation. 2002;  106 1211-1218
• 11 Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes.  Diabetologia. 2005;  48 1684-1699
• 12 Jeppesen J, Hansen TW, Rasmussen S, Ibsen H, Torp-Pedersen C, Madsbad S. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease: a population-based study.  J Am Coll Cardiol. 2007;  49 2112-2119
• 13 Dornhorst A. Insulinotropic meglitinide analogues.  Lancet. 2001;  358 ((9294)) 1709-1716
• 14 Shaw JA, Chin-Dusting JP, Kingwell BA, Dart AM. Diurnal variation in endothelium-dependent vasodilatation is not apparent in coronary artery disease.  Circulation. 2001;  103 806-812
• 15 Etsuda H, Takase B, Uehata A, Kusano H, Hamabe A, Kuhara R. et al . Morning attenuation of endothelium-dependent, flow-mediated dilation in healthy young men: possible connection to morning peak of cardiac events?.  Clin Cardiol. 1999;  22 417-421
• 16 Wolever TM, Chiasson JL, Csima A, Hunt JA, Palmason C, Ross SA. et al . Variation of postprandial plasma glucose, palatability, and symptoms associated with a standardized mixed test meal versus 75 g oral glucose.  Diabetes Care. 1998;  21 336-340
• 17 Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID. et al . Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis.  Lancet. 1992;  340 ((8828)) 1111-1115
• 18 Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA. et al . Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force.  J Am Coll Cardiol. 2002;  39 257-265
• 19 Newey VR, Nassiri DK. Online artery diameter measurement in ultrasound images using artificial neural networks.  Ultrasound Med Biol. 2002;  28 209-216
• 20 Sidhu PS. Comparison of Doppler ultrasound, magnetic resonance angiographic techniques and catheter angiography in evaluation of carotid stenosis.  Clin Radiol. 2002;  57 232
• 21 Lind L, Hall J, Larsson A, Annuk M, Fellstrom B, Lithell H. Evaluation of endothelium-dependent vasodilation in the human peripheral circulation.  Clin Physiol. 2000;  20 440-448
• 22 Mori Y, Miura K, Mine T, Tajima N. Role of early insulin secretion in postglucose-loading hyperglycemia and postfat-loading hyperlipidaemia: comparing nateglinide and glibenclamide for acute effects on insulin secretion in OLETF rats.  Diabetes Obes Metab. 2004;  6 422-431
• 23 Schmoelzer I, Wascher TC. Effect of repaglinide on endothelial dysfunction during a glucose tolerance test in subjects with impaired glucose tolerance.  Cardiovas Diabetol. 2006;  5 9
• 24 Shimabukuro M, Higa N, Takasu N, Tagawa T, Ueda S. A single dose of nateglinide improves post-challenge glucose metabolism and endothelial dysfunction in Type 2 diabetic patients.  Diabet Med. 2004;  21 983-986
• 25 Ceriello A, Cavarape A, Martinelli L, Da Ros R, Marra G, Quagliaro L. et al . The post-prandial state in Type 2 diabetes and endothelial dysfunction: effects of insulin aspart.  Diabet Med. 2004;  21 171-175
• 26 Malmberg K, Ryden L, Wedel H, Birkeland K, Bootsma A, Dickstein K. et al . Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity.  Eur Heart J. 2005;  26 650-661
• 27 Mehta SR, Yusuf S, Diaz R, Zhu J, Pais P, Xavier D. et al . Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial.  JAMA. 2005;  293 437-446
• 28 Kragelund C, Snorgaard O, Kober L, Bengtsson B, Ottesen M, Hojberg S. et al . Hyperinsulinaemia is associated with increased long-term mortality following acute myocardial infarction in non-diabetic patients.  Eur Heart J. 2004;  25 1891-1897
• 29 Vicent D, Ilany J, Kondo T, Naruse K, Fisher SJ, Kisanuki YY. et al . The role of endothelial insulin signaling in the regulation of vascular tone and insulin resistance.  J Clin Invest. 2003;  111 1373-1380
• 30 Goalstone ML, Natarajan R, Standley PR, Walsh MF, Leitner JW, Carel K. et al . Insulin potentiates platelet-derived growth factor action in vascular smooth muscle cells.  Endocrinology. 1998;  139 4067-4072
• 31 Okouchi M, Okayama N, Omi H, Imaeda K, Fukutomi T, Nakamura A. et al . The antidiabetic agent, gliclazide, reduces high insulin-enhanced neutrophil-transendothelial migration through direct effects on the endothelium.  Diabetes Metab Res Rev. 2004;  20 232-238
• 32 Bellin C, Wiza DH de, Wiernsperger NF, Rosen P. Generation of reactive oxygen species by endothelial and smooth muscle cells: influence of hyperglycemia and metformin.  Horm Metab Res. 2006;  38 732-739

Correspondence